The recommended dosage of Koselugo is 25 mg/m2 orally twice daily (approximately every 12 hours) until disease progression or unacceptable toxicity.
Koselugo can be taken with or without food. The recommended dose of Koselugo based on body surface area (BSA) is shown in Table 1.
The recommended dose reductions for adverse reactions are provided in Table 2.
Dosage modifications for adverse reactions are in Table 3.
Reduce the recommended dosage of Koselugo to 20 mg/m2 orally twice daily in patients with moderate hepatic impairment (Child-Pugh B). The recommended dosage of Koselugo for use in patients with severe hepatic impairment (Child-Pugh C) has not been established.
Strong or Moderate CYP3A4 Inhibitors or Fluconazole Avoid coadministration of strong or moderate CYP3A4 inhibitors or fluconazole with Koselugo. If coadministration with strong or moderate CYP3A4 inhibitors or fluconazole cannot be avoided, reduce the Koselugo dosage as recommended in Table 5. After discontinuation of the strong or moderate CYP3A4 inhibitor or fluconazole for 3 elimination half-lives, resume the Koselugo dose that was taken prior to initiating the inhibitor or fluconazole.
from FDA,2024.01
Koselugo is a carefully developed small molecule MEK inhibitor (also known as a ···【more】
Release date:2024-08-22Recommended:149
Koselugo is a class of finely designed small molecule MEK blockers (also known a···【more】
Release date:2024-08-22Recommended:120
Koselugo is a precisely targeted small molecule MEK inhibitor with a therapeutic···【more】
Release date:2024-08-22Recommended:147